Thorne HealthTech
clinical research studies support brand and partnerships | Thorne HealthTech
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2021
Slide
25 of 45
Related slides by other companies
Alkermes
Investor Day
March 2021
preclinical efforts inform the clinical development strategy preclinical research clinical research molecular design confirmed selectivity demonstrated efficacy first in human studies signal seeking studies receptor selectivity maintained potency cell cell expansion minimal expansion of combination with anti mouse determined recommended phase dose from safety and data responses in multiple tumor types and in combination with anti pivotal studies combination with demonstrate efficacy with complementary mechanisms potential expansion of clinical program growth factor pathway inhibitors chemotherapy radiation other agents new combinations new indications new collaborations a sab at oft | Alkermes
SmileDirectClub
Investor Presentation
May 2021
journal of dental research and reports clinical study confirms effectiveness of clear aligner care | SmileDirectClub
NeuroSense Therapeutics
Investor Presentation
June 2023
phase a study design | NeuroSense Therapeutics
Avenue Therapeutics
IPO
October 2022
completed clinical studies and demonstrated safety across trials | Avenue Therapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io